

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

**Identification of a novel glucuronyltransferase from *Streptomyces*
chromofuscus ATCC 49982 for natural product glucuronidation**

Jie Ren • Caleb Don Barton • Kathryn Eternity Sorenson • Jixun Zhan

Department of Biological Engineering, Utah State University, 4105 Old Main Hill,
Logan, UT 84322-4105, USA

Correspondence: Jixun Zhan

jixun.zhan@usu.edu

Abstract

Glycosylation is an effective way to increase the polarity of natural products. UDP-Glucuronyltransferases (UGTs) are commonly observed and extensively studied in phase II drug metabolism. However, UGTs in microorganisms are not well studied, which hampered the utilization of this type of enzyme in microbial glucuronidation of natural products. Screening of five actinomycete strains showed that *Streptomyces chromofuscus* ATCC 49982 can convert diverse plant polyphenols into more polar products, which were characterized as various glucuronides based on their spectral data. Analysis of the genome of this strain revealed a putative glucuronidation gene cluster that contains a UGT gene (*gcaC*) and two UDP-glucuronic acid biosynthetic genes (*gcaB* and *gcaD*). The *gcaC* gene was cloned and heterologously expressed in *Escherichia coli* BL21(DE3). Incubation of the purified enzyme with resveratrol and UDP-glucuronic acid led to the production of resveratrol-4'-O- β -D-glucuronide and resveratrol-3-O- β -D-glucuronide, allowing GcaC to be characterized as a flexible UGT. The optimal *in vitro* reaction pH and temperature for GcaC are 7.5 and 30 °C, respectively. Its activity can be stimulated by Ca^{2+} , Mg^{2+} and Mn^{2+} , whereas Zn^{2+} , Cu^{2+} and Fe^{2+} showed inhibitory effects. Furthermore, GcaC has a broad substrate specificity, which can glucuronidate various substrates besides resveratrol, including quercetin, ferulic acid, vanillic acid, curcumin, vanillin, chrysin, zearalenone, and apigenin. The titers of resveratrol-4'-O- β -D-glucuronide and resveratrol-3-O- β -D-glucuronide in *E. coli*-GcaC were 78.381 ± 0.366 mg/L and 14.991 ± 0.248 mg/L from 114.125 mg/L resveratrol within 3 hours. Therefore, this work provides an effective way to produce

glucuronides of resveratrol and other health-benefitting natural products.

Key points

- A novel versatile microbial UDP-glucuronyltransferase was discovered and characterized from *Streptomyces chromofuscus* ATCC 49982.
- The UDP-glucuronyltransferase was expressed in *Escherichia coli* and can convert resveratrol into two glucuronides both *in vitro* and *in vivo*.
- The UDP-glucuronyltransferase has a highly flexible substrate specificity and is an effective tool to prepare mono- or diglucuronides of bioactive molecules.

Keywords *Streptomyces chromofuscus* · flexible substrate specificity · monoglucuronide · diglucuronide · microbial glucuronyltransferase

Introduction

Plant polyphenols are an important group of compounds with diverse chemical structures (Harborne and Baxter 1999; Tsao 2010). Stilbenoids and flavonoids are representative examples of polyphenols which are rich in commonly consumed fruits and vegetables, and both animal and human clinical studies showed their health-promoting effects and antioxidant characteristics (Rice-Evans 2001; Thilakarathna and Rupasinghe 2013). However, low water solubility and poor bioavailability often limits the beneficial effects of polyphenols. Introduction of polar groups such as sugar moieties into the structure is a widely used approach to improve the water solubility of bioactive molecules. As such, discovery of novel and versatile glycosyltransferases is important for adding new enzymes into the biocatalytic toolbox.

Sugar moieties often play important roles in binding of drugs to biological targets. They may also be involved in other biochemical processes such as distribution, metabolism, and excretion properties of drugs, which can affect the efficacy of its oral administration (Thorson et al. 2004; Weymouth-Wilson 1997; Yu et al. 2002). Glycosylated compounds often exhibit increased water-solubility, intestinal absorption, biological half-life, physicochemical stability and bioavailability for medical and cosmetic applications, while may also have lower toxicity compared to their aglycon forms (Bowles et al. 2005; Cai et al. 2013; Gachon et al. 2005; Imai et al. 2012; Kaminaga et al. 2003). Digitoxin, amphotericin, vancomycin, streptomycin, and daunomycin are some examples of the most biologically active natural products and commonly used therapeutics, with one or more sugar moieties (Pandey et al. 2014).

Sugar moieties can also contribute to other biological properties of natural products. For instance, the glucuronic acid moieties of glycyrrhizin are essential for its sweet taste (Chung et al. 2020).

Glycosyltransferases are the enzymes responsible for transferring sugar moieties from sugar donors to acceptors to yield corresponding glycosides. Microorganisms are a rich source of both natural products and natural product biosynthetic enzymes. Actinomycetes, the most ubiquitous group of gram-positive filamentous bacteria, are well characterized for their metabolic versatility (Nawani et al. 2013; Prakash et al. 2013). For example, they can decompose organic matter (such as cellulose) which is important for the carbon cycle and maintaining the soil structure (Kim 2016; Priyadharsini and Dhanasekaran 2015). In addition, actinomycetes can also produce various commercial products, such as pharmaceuticals (antibiotics, antitumor agents, etc) and nutraceuticals (Prakash et al. 2013; Remya and Vijayakumar 2008). Furthermore, many actinomycete genera produce industrially important enzymes applied in biotechnological applications and biomedical fields, such as amylases, cellulases, chitinases, xylanases, and proteases (Mehnaz et al. 2017; Nawani et al. 2013).

Glucuronidation is one of the common glycosylation reactions in nature. UDP-Glucuronyltransferases (UGTs) are the enzymes involved in glucuronidation, which are widely observed in metabolism of xenobiotics and endogenous components (bilirubin, bile acids, and certain hormones) during phase II metabolism, a common detoxification pathway in the human body (De Wildt et al. 1999; Wilkinson et al. 2008). There are mainly two phases for drug metabolism, namely functionalization reactions and

111 conjugation reactions. Glucuronidation is one of the phase II conjugation reactions. It
112 was predicted that about 10% of the top 200 prescribed drugs recorded in USA are fully
113 or partially metabolized by UGTs. UGTs transfer the glucuronic acid moiety from
114 uridine 5'-diphosphoglucuronic acid (UDP-glucuronic acid) to various exogenous and
115 endogenous compounds. They often work with cytochrome P450 enzymes (CYPs) to
116 metabolize most hepatically cleared drugs.

117 Many fields such as drug development, sports drug testing, and the detection of
118 agricultural residues often require the identification, quantification, and
119 pharmacological evaluation of the glucuronidated metabolites (Wilkinson et al. 2011).
120 However, chemical approaches like the Koenigs-Knorr reaction used for
121 glucuronidation often suffer from poor yields and side reactions, as well as tedious
122 protection-deprotection of the hydroxyl groups of sugar moieties (Engstrom et al. 2006;
123 Stachulski et al. 2006). Enzymatic preparation of glucuronides represents a “green”
124 alternative because of the selectivity, mild conditions and elimination of the need of
125 toxic chemical reagents. Discovery of efficient and versatile UGTs is critical for the
126 development of feasible and viable production process of glucuronides.

127 In our ongoing effort of discovering novel enzymes for natural product
128 glycosylation, we found *Streptomyces chromofuscus* ATCC 49982 can convert
129 resveratrol and several other natural products to corresponding glucuronides. We
130 analyzed the genome of this strain and discovered a putative UGT gene flanked by two
131 UDP-glucuronic acid biosynthetic genes. The UDP gene was then cloned and
132 heterologously expressed in *Escherichia coli* BL21(DE3). The enzyme was

functionally characterized through *in vitro* reactions and its optimal reaction conditions were investigated. This enzyme is highly versatile and can convert a variety of substrates into monoglucuronides or diglucuronides. Therefore, this UGT represents a useful tool for the synthesis of glucuronidated metabolites. We also used the engineered *E. coli* strain to produce the two resveratrol glucuronides and the optimal bioconversion conditions were studied. In conclusion, the versatile UGT cloned and characterized from microorganism in this work lays the foundation for the microbial production of valuable glucuronides.

Materials and methods

General equipment and experimental materials

Agilent 1200 HPLC instrument with an Agilent Eclipse Plus-C₁₈ column (5 μ m, 250 mm \times 4.6 mm) was used to analyze and purify the products. The samples were eluted with methanol-water (5:95 to 95:5 over 35 minutes, v/v, containing 0.1 % formic acid) at a flow rate of 1 mL/min. Low-resolution ESI-MS spectra were obtained on an Agilent 6130 single quadrupole LC-MS in the negative mode to confirm the molecular weights of glucuronides. All purified compounds were dissolved in deuterated dimethyl sulfoxide (DMSO-*d*₆) to collect the NMR spectra on a Bruker Avance III HD Ascend-500 NMR instrument (500 MHz for ¹H NMR and 125 MHz for ¹³C NMR). The chemical shift (δ) values are given in parts per million (ppm). The coupling constants (*J* values) are reported in hertz (Hz).

Phusion High-Fidelity DNA polymerase, restriction enzymes and T4 DNA ligase were purchased from New England Biolabs. PCR reactions were conducted with an

Arktik Thermal Cycler (Thermo Scientific). Genomic DNA extraction was performed using the Quick-DNA™ Fungal/Bacteria DNA Miniprep Kit (Zymo Research, USA). Plasmid extraction was performed using the Thermo Scientific GeneJET Plasmid Miniprep Kit (Thermo Scientific). Primers were ordered from Thermo Scientific and dissolved in Tris-EDTA (TE) buffer to the concentration of 100 ng/mL. Standard compounds like resveratrol, quercetin, curcumin, vanillic acid, ferulic acid, vanillin, chrysin, zearalenone, apigenin, resibufogenin, tetracycline were purchased from Sigma-Aldrich (USA). HisPur™ Ni-NTA resin, Luria-Bertani (LB) medium, yeast and malt extracts were purchased from Fisher Scientific (Rockford, IL, USA). Bradford assay solution was purchased from TCI America (Portland, OR, USA). Solvents and all other chemicals were purchased from Fisher Scientific. Milli-Q water was used throughout this study.

Strains, vectors, media, and culture conditions

Streptosporangium roseum No. 79089 (NRRL 2505) was provided by the ARS Culture Collection (NRRL) of the United States Department of Agriculture. *Streptomyces roseiscleroticus* ATCC 53903, *Actinomadura hibisca* P157-2 (ATCC 53557), and *S. chromofuscus* ATCC 49982 were obtained from the American Type Culture Collection (ATCC). *Streptomyces* sp. FERM BP-2474 was acquired from Patent and Bio-Resource Center, National Institute of Advanced Industrial Science and Technology, Japan.

E. coli XL1-Blue and BL21(DE3) were both purchased from Agilent. *E. coli* XL1-Blue was used for routine gene cloning and plasmid propagation. *E. coli* BL21(DE3) was used for protein expression and *in vivo* biotransformation. The pJET1.2 (Thermo

Fisher Scientific, USA) and pET28a (+) (Millipore Sigma, USA) vectors were used, respectively, to clone and express UGT. The *E. coli* strains were routinely grown at 37 °C on LB agar plates or in liquid LB medium (Fisher Scientific, USA). When necessary, carbenicillin (50 µg/mL) and kanamycin (50 µg/mL) were supplemented into the culture media for selecting correct clones. *S. chromofuscus* ATCC 49982 was grown on YM plate (4 g/L yeast extract, 10 g/L malt extract, 4 g/L glucose, and 20 g/L agar) or in YM broth (4 g/L yeast extract, 10 g/L malt extract, and 4 g/L glucose) at 28 °C. Recombinant UGT was expressed in *E. coli* BL21(DE3) at 28 °C. Isopropyl-1-thio-β-D-galactopyranoside (IPTG) (Gold Biotechnology, USA) was used at 200 µM to induce protein expression in *E. coli* BL21(DE3).

Screening of glucuronidating actinomycete strains

To test the ability of actinomycetes to glucuronidate resveratrol, we screened five strains, namely, *S. roseum* No. 79089, *S. roseiscleroticus* ATCC 53903, *A. hibisca* ATCC 53557, *Streptomyces* sp. FERM BP-2474, and *S. chromofuscus* ATCC 49982. These bacteria were grown in 50 mL of YM medium in a rotary shaker at 250 rpm and 28 °C for 3 days.

Resveratrol (4 mg) was dissolved in DMSO and added into each culture. The cultures were incubated under the same conditions for an additional 4 days. After that, 1 mL of fermentation broth was sampled and centrifuged at 15,000 ×g for 10 min. The supernatant was analyzed by HPLC at 300 nm. In order to check whether *S. chromofuscus* ATCC 49982 can glucuronidate other substrates, quercetin, ferulic acid, and vanillic acid were incubated with the culture of this strain in a similar way. The

supernatant was analyzed by HPLC at 350 nm (quercetin) or 300 nm (ferulic acid and vanillic acid) using the same HPLC conditions for resveratrol.

Extraction and purification of compounds

To isolate the biotransformation products of resveratrol for structure elucidation, *S. chromofuscus* ATCC 49982 was cultivated in 1-L Erlenmeyer flasks, containing 250 mL of YM medium, to biotransform 20 mg of resveratrol. After 4 days, the fermentation broth was centrifuged at 4,000 ×g for 10 min. After water in the supernatant was evaporated, the residue was dissolved in 2 mL of methanol. The sample was subjected to Sephadex LH-20 column chromatography, and eluted with methanol-water (1:1, v/v). The products-containing fraction was further separated by reverse phase HPLC, and eluted with methanol-water (10-50%, 0-17 min; 50-95%, 17-22 min) containing 0.1% formic acid (v/v) to yield **1** (3.6 mg) and **2** (2.8 mg). Products **1** and **2** were also used to prepare a standard curve to quantify the formation of these products in the *in vitro* and *in vivo* reactions.

A similar procedure was used to isolate the biotransformation products of quercetin, ferulic acid and vanillic acid for structure elucidation except the HPLC methods for final compound purification. The gradient elution method with methanol-water (20-40%, 0-2 min; 40%, 2-15 min; 40-95%, 15-20 min) was used to yield product **3** (7.4 mg) and **4** (5.8 mg). The gradient elution method with methanol-water (5-60%, 0-15 min; 60-95%, 15-16 min; 95%, 16-18 min) was used to yield product **5** (4.8 mg), **6** (3.0 mg) and **7** (1.2 mg). All purified products were subjected to NMR analysis. The purified products were dissolved in DMSO-*d*₆. Their chemical structures were

characterized based on the NMR data (Supplementary Material).

Genome analysis and amplification of the putative UGT gene from *S. chromofuscus* ATCC 49982

The genomic DNA was extracted from *S. chromofuscus* ATCC 49982 using the Quick-DNA™ Fungal/Bacterial Microprep Kit (Zymo Research, USA) by following the manufacturer's standard procedure. The 454 next-generation sequencing system and Rapid Annotation using Subsystem Technology (RAST) were used respectively to sequence and annotate the genomic DNA of *S. chromofuscus*. The glucuronidation (*gca*) gene cluster was deposited into GenBank under the accession number MZ666424. The detailed functions of each gene in the gene cluster was predicted based on BLAST analysis of the corresponding amino acid sequences.

Plasmids were extracted from *E. coli* via the GeneJET Plasmid Miniprep Kit (Thermo Fisher Scientific). Primers were synthesized by Thermo Scientific (5'-AATTGTTTAAACCATATGCGAGTACTGTTCCACCAC-3' and 5'-AATTGCTAGCAAGCTTTCAGACGATCTTCTGCAGGTC-3'). The primers (1 μM), genomic DNA (0.2 μL), dNTP mix (200 μM), 5× buffer (4 μL), DMSO (0.4 μL), Phusion High-Fidelity DNA Polymerase (0.2 μL at 2 U/μL) and nuclease-free water were mixed to 20 μL for amplification of the UGT (*gcaC*) gene (1,209 bp). The PCR program began with an initial denaturation at 95 °C for 5 min, and then 20 cycles of touchdown program (95 °C for 30 s, annealing at 70 °C for 40 s, decreasing 0.5 °C per cycle, and extension at 72 °C for 100 s), followed by 20 cycles of regular program (95 °C for 30 s, annealing at 60 °C for 40 s, and extension at 72 °C for 100 s), and finally, 68 °C for

15 min of extension.

Construction of cloning and expression plasmids

After purification with a GeneJET Gel Extraction Kit, the target PCR product was ligated into the pJET1.2 cloning vector to yield pJR34 (pJET1.2-*gcaC*). After the pJR34 plasmid was confirmed by digestion check and sequencing using the Sanger method, the gene was excised from pJR34 and introduced to the pET28a expression vector between the *NdeI* and *HindIII* restriction sites to yield expression plasmid pJR36 (pET28a-*gcaC*). The ligation product was transferred into *E. coli* XL1-Blue competent cells through chemical transformation, and the transformants were selected on LB agar with 50 µg/mL kanamycin. The correct plasmids were confirmed by digestion check with *NdeI* and *HindIII*.

Heterologous expression of GcaC and *in vivo* biotransformation of resveratrol in *E. coli* BL21(DE3)

The expression plasmid pJR36 was transferred into *E. coli* BL21(DE3) through chemical transformation. The correct transformant of *E. coli* BL21(DE3)-pJR36 was picked from LB agar into 5 mL of LB medium supplemented with kanamycin (50 µg/mL), incubating at 37 °C with shaking (250 rpm) for about 12 hours. Then 500 µL of the seed culture was inoculated into 50 mL of LB broth with kanamycin (50 µg/mL) with shaking at 250 rpm and 37 °C. When the OD₆₀₀ reached between 0.4 and 0.6, protein expression was induced with 200 µM IPTG, and the culture was maintained at 28 °C for an additional 16 hours with shaking at 250 rpm. After protein expression, 0.35 mM resveratrol and 0.11 M glucose were added as the substrates. The culture was

incubated under the same conditions for an additional 48 hours. After fermentation, 1 mL of the culture was sampled and centrifuged at 15,000 ×g for 10 min. 100 µL of the supernatant was subjected to analysis on HPLC (at 300 nm).

Functional characterization of GcaC through *in vitro* enzymatic reactions

GcaC was purified as described in Supplementary Material. We characterized the function of GcaC by reacting the enzyme with the substrate resveratrol. Enzymatic assays were conducted in a 100-µL reaction system, which included 20 mM Tris-HCl (pH 8.0), 2.2 mM substrate, 1 mM MgCl₂, 2 mM sugar donor (UDP-glucuronic acid), and 23.7 µg purified recombinant GcaC protein. The mixtures were thoroughly mixed and incubated at 30 °C for 6 hours, and then 200 µL of HPLC-grade methanol was added to terminate the reaction. The reaction mixtures were centrifuged at 13,000 ×g for 10 min, and supernatants were collected to analyze the products by LC-MS.

The substrate specificity of GcaC was investigated using additional sugar-acceptor substrates, including curcumin, quercetin, ferulic acid, vanillic acid, vanillin, chrysin, apigenin, zearalenone, tetracycline and resibufogenin. In terms of sugar-donor substrates, another structurally similar sugar-donor substrate UDP-glucose was also reacted with resveratrol, besides UDP-glucuronic acid. Reaction products were analyzed by LC-MS after centrifugation.

Determination of the optimal *in vitro* reaction conditions

Purified resveratrol glucuronides were used to establish standard curves for quantifying product formation. The effects of reaction temperature, pH and metal ions on the catalytic activity of GcaC were examined. To determine the optimum temperature, the

reaction mixtures with resveratrol as the substrate were incubated at different temperatures (20, 25, 30, 35, 40, 45, and 50 °C) for 6 hours. Glucuronidation reactions were conducted as described before except with 1.0 mM resveratrol. In order to find out the optimum pH, GcaC was reacted with resveratrol at 30 °C in 200 mM phosphate buffer with different pH values (pH 4.5, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, and 9.0). The conversion rate of resveratrol was quantified by HPLC. Control reaction was conducted under the same conditions, but without GcaC. Different metal ions such as CaCl₂, CuCl₂, FeSO₄, MgCl₂, MnCl₂, and ZnCl₂ were also tested. Control reaction was performed under the same conditions without adding these metal ions. The experiments were carried out with individually divalent metal ion at the final concentration of 10 mM, and UDP-glucuronic acid and resveratrol were used as sugar donor and sugar acceptor, respectively. All reactions were performed in triplicate and conversion rates were expressed as the mean ± standard deviation.

Whole-cell bioconversion of resveratrol into resveratrol glucuronides by *E. coli* BL21(DE3)-pJR36

E. coli BL21(DE3)-pJR16 was grown and induced as described above. The cells were collected by centrifugation for whole-cell bioconversion after IPTG induction at 28 °C for 16 hours. Phosphate buffer was used to re-suspend the cells, and cell density was determined using a UV-Vis spectrophotometer (Thermo Scientific, Rockford, USA) by recording the OD₆₀₀ value. In order to determine the whole-cell bioconversion conditions, different pH values (pH 4.5, 5.5, 6.0, 6.5, 7.0, 7.5, and 8.5), temperatures (25, 30, 35, 40, and 45 °C), cell densities (OD₆₀₀ 2.5, 5, 7.5, 10, 12.5, and 15), reaction

times (1, 2, 3, 4, and 5 h) and substrate concentrations (0.25, 0.5, 1.0, 1.5, 2.0 and 2.5 mM) were investigated. Product formation was quantified by HPLC. Finally, the whole-cell biotransformation experiment was performed in a 1-L reaction system under the optimal conditions. The reaction consisted of *E. coli* BL21(DE3)-pJR36 cells (OD₆₀₀ 10.0) and 0.5 mM resveratrol, and the bioconversion process was performed at 40 °C, pH 6.5, and 250 rpm for 3 hours.

Results

Screening of different actinomycete strains for the ability to glycosylate resveratrol

Actinomycetes are known to produce a variety of bioactive natural products and contain abundant biosynthetic enzymes. We hypothesized that some of these strains may have versatile UGTs that can introduce the glucuronic acid moiety to plant polyphenols such as resveratrol. To this end, resveratrol was incubated with five different strains, including *S. roseum* No. 79089, *S. resei*scleroticus ATCC 53903, *A. hibisca* P157-2, *Streptomyces* sp. FERM BP-2474, and *S. chromofuscus* ATCC 49982. HPLC analysis revealed that two more polar metabolites, at 15.5 min for product **1** and 17.0 min for product **2** respectively, were synthesized from resveratrol by *S. chromofuscus* ATCC 49982 (Fig. 1a). The UV absorption patterns of the products were both similar to that of resveratrol, suggesting that these two polar products are derivatives of the substrate (Fig. 1b). However, no products were detected in the other four strains.

Characterization of the two biotransformed products of resveratrol by *S. chromofuscus* ATCC 49982

ESI-MS spectra of both **1** (Fig. 1d) and **2** (Fig. 1e) showed the same corresponding quasimolecular ions $[M-H]^-$ at m/z 402.8 and $[2M-H]^-$ at m/z 806.7, respectively. Therefore, products **1** and **2** have the same molecular weight of 404, which is 176 mass units larger than the substrate resveratrol, suggesting that a glucuronic acid moiety was added to different hydroxyl groups of resveratrol.

In order to elucidate the chemical structures, two purified products **1** and **2** were subjected to NMR analysis (Figures S1-S10). The ^{13}C NMR spectra of **1** (Figure S2) and **2** (Figure S7) both revealed 20 carbon signals. In addition to the 14 signals belonging to resveratrol, six additional carbon signals at δ_{C} 170.5, 100.3, 76.2, 75.9, 73.4, and 71.8 for **1** and δ_{C} 170.1, 100.5, 77.2, 75.8, 72.9, and 71.4 for **2** were found in the spectra, further suggesting that a sugar moiety was added to resveratrol at one of its hydroxyl groups. Unlike glucose and other common sugars, this sugar moiety has a carbon signal at around δ_{C} 170, indicating the presence of a carboxyl group. Both the ^1H and ^{13}C signals of this sugar moiety supported the presence of a glucuronic acid moiety. As shown in the ^1H NMR spectra (Figures S1 and S6), the anomeric proton signals at δ_{H} 5.07 (d, $J = 7.5$ Hz), and 4.99 (d, $J = 7.7$ Hz) of **1** and **2**, respectively, indicated the β -configuration of these two compounds for the glucuronic acid moiety. HMBC spectrum of **1** revealed the correlation of H-1" at δ_{H} 5.07 to C-4' at δ_{C} 156.9 (Figures 2 and S5), which confirmed that **1** has a glucuronic acid moiety at C-4'. Similarly, H-1" at δ_{H} 4.99 of **2** had HMBC correlation to C-3 at δ_{C} 158.4, indicating that the glucuronic acid moiety was introduced at C-3 (Figures 2 and S10). Therefore, products **1** and **2** were characterized as resveratrol-4'-O- β -D-glucuronide and

resveratrol-3-O- β -D-glucuronide, respectively. The NMR data of **1** and **2** are consistent with those reported in literature (Wang et al. 2004).

Characterization of the biotransformed products of quercetin, ferulic acid and vanillic acid by *S. chromofuscus* ATCC 49982

To check whether *S. chromofuscus* can also glucuronidate other natural products, quercetin, ferulic acid and vanillic acid were incubated with *S. chromofuscus* respectively. We found that all these three substrates can be glucuronidated into one or two glucuronides (Fig. 3).

When quercetin was used as substrate, HPLC analysis (Fig. 3a) showed that two polar products at 16.1 and 18.8 min, respectively, were formed from quercetin. Two products showed the similar UV spectra (Figures S11a and S11b) to the substrate. ESI-MS spectra (Figures S12a and S12b) of both **3** and **4** showed the corresponding quasi-molecular ion $[M-H]^-$ at m/z 476.9 and 476.6, respectively. Therefore, products **3** and **4** have the same molecular weight of 478, which is 176 mass units larger than the substrate quercetin, indicating that a glucuronic acid moiety was added to different hydroxyl groups of quercetin.

When ferulic acid was used as the substrate, a polar product **5** at 12.8 min was detected by HPLC (Fig. 3b). Two more polar products **6** and **7** appeared at 9.7 and 10.8 min when vanillic acid was incubated with *S. chromofuscus* ATCC 49982 (Fig. 3c). These products showed the similar UV spectra (Figures S11c-e) to the corresponding substrates. The ESI-MS spectra (Figures S12c-e) of **5-7** showed a $[M-H]^-$ ion peak at m/z 368.9, 342.9, and 342.9, respectively, indicating that their molecular weights are

370, 344 and 344 Da, which are consistent with the addition of a glucuronic acid moiety to the substrates ferulic acid and vanillic acid. Therefore, *S. chromofuscus* was found to be able to glucuronidate various phenolic natural products.

The NMR spectra of products **3-7** were collected (Figures S13-S37). The ^{13}C NMR spectra (Figures S14 and S19) of compounds **3** and **4** both showed 21 carbon signals. In addition to the signals from quercetin, six additional carbon signals at δ_{C} 170.1, 99.1, 75.6, 75.4, 72.8, and 71.2 for **3** and δ_{C} 169.7, 101.0, 76.0, 75.8, 73.8, and 71.3 for **4** were found in the spectra. These signals were similar to those from the glucuronic acid moiety of **1** and **2**, thus suggesting that a glucuronic acid moiety was added to one of the hydroxyl groups in quercetin. As shown in the ^1H NMR spectra (Figures S13 and S18), the anomeric proton signals at δ_{H} 5.29 (d, $J = 7.3$ Hz), and 5.50 (d, $J = 7.5$ Hz) of **3** and **4**, respectively, indicated the β -configuration of the sugar moiety in these two compounds. HMBC spectrum of **3** revealed the correlation of H-1" at δ_{H} 5.29 to C-7 at δ_{C} 162.2 (Figures 2 and S17), which confirmed that **3** has a glucuronic acid moiety at C-7. Similarly, H-1" of **4** at δ_{H} 5.50 had HMBC correlation to C-3 at δ_{C} 133.0, indicating that the glucuronic acid moiety was introduced at C-3 (Figures 2 and S22). Therefore, products **3** and **4** were characterized as quercetin-7-O- β -D-glucuronide and quercetin-3-O- β -D-glucuronide, respectively. The NMR data of **3** and **4** are consistent with those reported in literature (Marvalin and Azerad 2011a).

The ^{13}C NMR spectrum of compounds **5** revealed 16 carbon signals. Compared to the substrate ferulic acid, there were six additional carbon signals at δ_{C} 170.2, 99.2, 76.1, 75.3, 72.9, and 71.4, further suggesting that a glucuronic acid moiety was added

to ferulic acid. As shown in the ^1H NMR spectrum (Figure S23), the anomeric proton signal of **5** at δ_{H} 5.13 (d, $J = 7.1$ Hz) indicated the β -configuration of the glucuronic acid moiety. HMBC spectrum of **5** revealed the correlation of H-1" (δ_{H} 5.13, d, $J = 7.1$ Hz) to C-4 at δ_{C} 147.8 (Figures 2 and S27), which confirmed that the position of glucuronic acid moiety is at C-4 of **5**. Therefore, **5** was characterized as ferulic acid-4-O- β -D-glucuronide. The NMR data were assigned based on the 1D and 2D NMR spectra for the first time.

The ^{13}C NMR spectra of both **6** (Figure S29) and **7** (Figure S34) showed 14 carbon signals. In addition to the eight carbon signals from vanillic acid, six additional carbon signals at δ_{C} 170.8, 99.2, 76.4, 74.7, 72.9, and 71.6 were observed for **6** and δ_{C} 170.4, 94.6, 75.9, 75.7, 72.3, and 71.6 for **7**, indicating that a glucuronic acid moiety was added to vanillic acid at different positions to yield the two products. As shown in the ^1H NMR spectra (Figures S28 and S33), the anomeric proton signals of **6** and **7** at δ_{H} 5.11 (d, $J = 6.1$ Hz) and 5.54 (d, $J = 7.5$ Hz), respectively, indicated the β -configuration of the glucuronic acid moiety in these compounds. HMBC spectrum of **6** revealed the correlation of H-1" at δ_{H} 5.11 to C-4 at δ_{C} 150.0 (Figures 2 and S32), which confirmed that **6** has a glucuronic acid moiety at C-4. Similarly, H-1" of **7** at δ_{H} 5.54 had HMBC correlation to C-7 at δ_{C} 164.4, indicating that the glucuronic acid moiety was introduced at C-7 (Figures 2 and S37). Therefore, **6** and **7** were characterized as vanillic acid-4-O- β -D-glucuronide and vanillic acid-7-O- β -D-glucuronide, respectively. The NMR data of compound **6** is consistent with those reported in literature (Almeida et al. 2017) and the NMR data of compound **7** were assigned based on the 1D and 2D NMR spectra for

the first time.

Discovery of a putative glucuronidation gene cluster from *S. chromofuscus* ATCC 49982

To find out which enzyme is responsible for the glucuronidation in *S. chromofuscus* ATCC 49982, we analyzed the genome of this strain that was previously sequenced by our group. Annotation of the genome indicated that there are more than 30 glycosyltransferases in *S. chromofuscus* ATCC 49982. To narrow down, we looked at the genes adjacent to these glycosyltransferase genes. A gene cluster (Fig. 4a) putatively involved in the glucuronidation was discovered, and the predicted functions of the genes are shown in Table 1. The five genes, named *gcaA-E*, were predicted to be TetR transcriptional regulator, UDP-glucose dehydrogenase, UDP-glucuronosyltransferase, UDP-glucose pyrophosphorylase, and MFS transporter, respectively. While *gcaA* and *gcaE* might be involved in the regulation of the gene cluster and sugar transport, respectively, *gcaB*, *gcaC* and *gcaD* were proposed to be involved in the biosynthesis and transfer of UDP-glucuronic acid (Fig. 4b). More specifically, GcaD (containing 320 amino acids or aa) generates UDP-glucose from glucose-1-phosphate as a UDP-glucose pyrophosphorylase, GcaB (484 aa) functions as a UDP-glucose dehydrogenase to synthesize UDP-glucuronic acid, and finally GcaC (402 aa) transfers the UDP-glucuronic acid moiety to a sugar acceptor such as resveratrol.

BLAST analysis of the amino acid sequence of GcaC revealed that it is homologous to a number of glycosyltransferases including a few uncharacterized UDP-

glucuronyl/UDP-glucosyltransferase, such as those from *Streptomyces malaysiensis* (GenBank accession number NIY63294.1, 408 aa, 70% identity) and *Streptomyces violaceusniger* (GenBank accession number AEM85024.1, 404 aa, 68% identity).

Although both genes are not functionally characterized so far, they still provide useful information to predict the function of GcaC.

Heterologous expression and purification of GcaC from *E. coli* BL21(DE3)

To identify the function of GcaC, we amplified this gene from the genomic DNA of *S. chromofuscus*, and ligated it to pET28a to yield the corresponding expression plasmid, pJR36 (pET28a-gcaC). The plasmid was then expressed in *E. coli* BL21(DE3) with IPTG induction. Ni-NTA column chromatography was used to purify the N-His₆-tagged GcaC from the cell lysate and the purified enzyme was analyzed by SDS-PAGE. As shown in Fig. 5a, GcaC (~43.4 kDa) was expressed and purified from *E. coli* BL21(DE3)-pJR36 to homogeneity and the isolation yield of this enzyme was 11.87 mg/L.

***In vitro* functional characterization of GcaC**

To check the function of purified GcaC, resveratrol was incubated with this enzyme in the presence of UDP-glucuronic acid. HPLC analysis showed that compared to the control (trace i, Fig. 5b), two polar products were formed from resveratrol (trace ii, Fig. 5b). Two products showed the similar UV spectra to the substrates. ESI-MS spectra (Figs. 5c and 5d) of these products showed the corresponding quasi-molecular ion [M-H]⁻ at *m/z* 402.9, respectively. Therefore, they have the same molecular weight of 404, which is 176 mass units larger than the substrate resveratrol, indicating that a glucuronic

acid moiety was added to different positions of resveratrol. Furthermore, the retention times of these two *in vitro* products were the same as those of resveratrol-4'-O- β -D-glucuronide and resveratrol-3-O- β -D-glucuronide produced in the *in vivo* biotransformation by *S. chromofuscus*. Formation of the two resveratrol glucuronides in the *in vitro* reactions allowed the characterization of GcaC as the responsible UGT in *S. chromofuscus*.

Broad substrate specificity of GcaC toward sugar acceptor substrates

To explore the substrate specificity of GcaC, this enzyme was reacted with different sugar donors and sugar acceptors. UDP-Glucose is structurally similar to UDP-glucuronic acid and the BLAST analysis of the sequence of GcaC suggested that this enzyme is homologous to a predicted UDP-glucuronyltransferase or UDP-glucosyltransferase from *S. malaysiensis* (Table 1). Therefore, we reacted resveratrol with UDP-glucose in the presence of GcaC. However, no products were formed from resveratrol (data not shown), indicating that GcaC is a specific UDP-glucuronyltransferase that strictly transfers UDP-glucuronic acid.

We next investigated the substrate specificity of GcaC to sugar acceptor substrates by reacting it with various natural products, including quercetin, ferulic acid, vanillic acid, curcumin, vanillin, chrysin, zearalenone and apigenin, with UDP-glucuronic acid in the presence of GcaC. When quercetin was used as the substrate, HPLC analysis (Fig. 6a) showed that six polar products were formed. All products showed the similar UV spectra (Figures S38a-f) to the substrate. ESI-MS spectra (Figures S39a-f) of **Q1-Q6** showed the corresponding quasi-molecular ion $[M-H]^-$ at m/z 653.0, 653.0, 476.9, 476.9,

476.9, and 476.9, respectively. Therefore, products **Q3-Q6** have the same molecular weight of 478, which is 176 mass units larger than the substrate quercetin, indicating that a glucuronic acid moiety was added to different hydroxyl groups of quercetin. Since quercetin has five free phenolic hydroxyl groups, we propose that the glucuronic acid moiety was introduced to four of these hydroxyl groups to generate the four monoglucuronides. Among these monoglucuronides, **Q3** and **Q4** had the same retention times as products **3** and **4**, which were characterized as quercetin-7-O- β -D-glucuronide and quercetin-3-O- β -D-glucuronide, respectively. The molecular weight of both **Q1** and **Q2** were found to be 654, which is 352 mass units larger than the substrate quercetin or 176 units larger than products **Q3-Q6**, suggesting that two glucuronic acid moieties were added to quercetin to form diglucuronides. Therefore, this enzyme not only adds the glucuronic acid moiety to different hydroxyl groups of quercetin, but also accepts the resulting monoglucuronides as the substrates to further generate diglucuronides.

When ferulic acid was incubated with GcaC, one polar product **F1** at 12.8 min was detected by HPLC (Fig. 6b). Similarly, one product **VA1** appeared at 9.7 min when vanillic acid was used as a sugar acceptor (Fig. 6c). Both products showed the similar UV spectra (Figures S38g and S38h) to the corresponding substrates. The ESI-MS spectra (Figures S39g and S39h) of **F1** and **VA1** showed a $[M-H]^-$ ion peak at m/z 368.9 and 342.9, respectively, indicating that their molecular weights are 370 Da and 344 Da, which are consistent with the addition of a glucuronic acid moiety to ferulic acid and vanillic acid, respectively. Furthermore, the retention times of **F1** and **VA1** are the same as **5** and **6** from the biotransformation by *S. chromofuscus* 49982, namely ferulic acid-

4-O- β -D-glucuronide and vanillic acid-4-O- β -D-glucuronide.

Meanwhile, when curcumin was used as the substrate, HPLC analysis showed that compared to the negative control (trace i, Fig. 6d), GcaC generated two polar products **C1** and **C2** (trace ii, Fig. 8d), at 21.8 and 25.3 min respectively. The two products had the UV spectra (Figures S38i and S38j) similar to that of the substrate. The ESI-MS spectra (Figures S39i and S39j) of the two products showed the $[M-H]^-$ ion peak at m/z 719.1 and 542.8, indicating that their molecular weights are 720 Da and 544 Da, respectively. These are consistent with a diglucuronide and a monoglucuronide of curcumin, whose molecular weight is 368 Da. This result further indicated that GcaC can transfer one or two glucuronic acid moieties to curcumin.

Similarly, we also used vanillin as the substrate, and one polar product **VN1** at 10.0 min was detected by HPLC (Fig. 6e). One product **CS1** was also observed at 22.0 min when chrysin was incubated with GcaC (Fig. 6f). Both products showed the similar UV spectra (Figures S38k and S38l) to their relative substrates. The ESI-MS spectra (Figures S39k and S39l) of **VN1** and **CS1** showed a $[M-H]^-$ ion peak at m/z 326.9 and 428.8, respectively, indicating that their molecular weights are 328 Da and 430 Da, which are consistent with the addition of a glucuronic acid moiety to vanillin and chrysin, respectively. Similarly, when zearalenone and apigenin were used as the substrates, HPLC analysis showed that compared to the negative controls (trace i, Figures 6g and 6h), GcaC generated a product **Z1** (trace ii, Fig. 6g) at 23.0 min from zearalenone and a product **A1** (trace ii, Fig. 6h) at 19.0 min from apigenin. The products showed the UV spectra (Figures S38m and S38n) similar to those of their substrates.

The ESI-MS spectrum (Figure S39m) of **Z1** exhibited the $[M-H]^-$ ion peak at m/z 493.1, which means the molecular weight is 494 Da and it is in accord with the addition of a glucuronic acid moiety to zearalenone with a molecular weight of 318. The ESI-MS spectrum (Figure S39n) of **A1** showed the $[M-H]^-$ ion peak at m/z 445.1, indicating that molecular weight is 446 Da. This is consistent with a monoglucuronide of apigenin, whose molecular weight is 270 Da. Therefore, GcaC synthesized the corresponding glucuronides from zearalenone and apigenin.

Other substrates, including tetracycline and resibufogenin, were also reacted with UDP-glucuronic acid in the presence of GcaC. However, no products were detected by HPLC (data not shown).

Determination of the optimal *in vitro* reaction conditions of GcaC

The effects of reaction temperature and pH on the GcaC-catalyzed glucuronidation were examined. Purified GcaC was incubated with resveratrol and UDP-glucuronic acid under different conditions. First, the reaction was conducted at different temperatures ranging from 20 °C to 50 °C. The conversion rates of resveratrol were quantified by HPLC and compared. As shown in Fig. 7a, GcaC has the highest glucuronidation activity at 30 °C with the highest conversion rate. When the temperature increased from 20 °C to 30 °C, the conversion rate of resveratrol increased from 29.61% to 70.85%. However, when the reaction temperatures were above 30 °C, the resveratrol conversion rate gradually decreased. Therefore, the optimum reaction temperature for GcaC was determined to be 30 °C.

Next, we determined the pH effect on the glucuronidation activity of GcaC. The

enzyme was reacted with resveratrol in 200 mM phosphate buffer at 30 °C but at different pH values, including 4.5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9. With the increase of pH from 4.5 to 7.5, the conversion rate of resveratrol by GcaC steadily increased from 7.8% to 59.3%. Nevertheless, when the pH value further increased to 9.0, the conversion rate decreased to 37.2% (Fig. 7b). Hence, the optimum pH for GcaC is 7.5.

Apart from temperature and pH effects, we also investigated the effect of various metal ions on the activity of GcaC. At 10 mM, we found that Ca^{2+} , Mg^{2+} , and Mn^{2+} had a stimulative function on the UGT activity of GcaC (Fig. 7c). With these three metal ions applied in the enzymatic reaction, the catalytic activity was 1.33, 1.27, and 1.09-fold higher than that of the control group, respectively. Among these three metal ions, Ca^{2+} has the strongest stimulating effect. By contrast, the activity of GcaC was inhibited when Cu^{2+} , Fe^{2+} , and Zn^{2+} were added into the reaction system. The conversion rate of resveratrol decreased from 52.3% to 39.1%, 48.6%, and 43.8% (Fig. 7c), respectively. In conclusion, the optimal *in vitro* reaction conditions for purified GcaC are at 30 °C, pH 7.5 with 10 mM of Ca^{2+} .

Optimized production of resveratrol-4'-O- β -D-glucuronide and resveratrol-3-O- β -D-glucuronide with the engineered *E. coli* BL21(DE3)

We next tested whether *E. coli* BL21(DE3)-pJR36 can convert resveratrol into the two glucuronides. To this end, resveratrol was incubated with the IPTG-induced broth of this engineered strain, with *E. coli* BL21(DE3)-pET28a as the negative control. As shown in Fig. 8a, compared to the commercial standard (trace i) and negative control (trace ii), incubation of resveratrol with *E. coli* BL21(DE3)-pJR36 yielded the

glucuronidation products **1** and **2**.

In vivo biotransformation of resveratrol by *E. coli* BL21(DE3)-pJR36 indicated that GcaC can generate resveratrol-4'-O- β -D-glucuronide as the major product from resveratrol in *E. coli*, which provides an alternative approach to biosynthesize this resveratrol glucuronide. Therefore, it is critical to discover the optimal conditions for this whole-cell bioconversion process. The effect of different cell concentrations on the formation of resveratrol glucuronides at 40 °C overnight was first investigated, ranging from OD₆₀₀ 2.5 to 15.0. In the presence of 1.5 mM resveratrol and 0.11 M glucose, we discovered that the conversion rate of resveratrol steadily increased with increasing cell concentrations within the range of OD₆₀₀ 2.5-10.0 (Fig. 8b). The conversion rate of resveratrol in the biotransformation system reached 53.8% when the OD₆₀₀ value was 10.0, which was 27.3% higher than the titer at OD₆₀₀ 2.5. However, further increase in cell concentration resulted in a drop of the conversion rate, indicating that oversaturated cells did not yield more products.

The conversion of resveratrol to its glucuronides was also determined by HPLC at different pH values (pH 4.5-8.5). When the reaction pH was 6.5, the conversion rate reached its highest level, namely 38.1% (Fig. 8c), which is 23.2% higher than that at pH 4.5. We next investigated the impact of temperature on the whole-cell conversion efficiency of resveratrol to its glucuronides. Specifically, *E. coli* BL21(DE3)-pJR36 cells (OD₆₀₀ 10.0) were incubated with resveratrol at different temperatures ranging from 25 to 45 °C in 200 mM phosphate buffer (pH 6.5). It was clearly proved that the higher temperature could effectively improve the conversion of resveratrol into

resveratrol-4'-O- β -D-glucuronide and resveratrol-3-O- β -D-glucuronide. The highest conversion rate reached 48.6% at 40 °C (Fig. 8d).

To determine how the bioconversion time affects the conversion rate of resveratrol in the engineered *E. coli* strain, we conducted a time course analysis for the conversion of 1.0 mM resveratrol to its glucuronides. The experiments were performed with GcaC-expressing *E. coli* BL21(DE3) strain (OD₆₀₀ 10.0) at 40 °C in 200 mM phosphate buffer (pH 6.5). The reaction was sampled at 1, 2, 3, 4 and 5 hours. Within the first 3 hours, the conversion rate of resveratrol increased from 18.0% to 34.8% (Fig. 8e). After that, the increase in the conversion rate slowed down gradually. Thus, we chose 3 hours as the preferred reaction time.

Substrate concentration can also affect the bioconversion rate. Therefore, we next tested different resveratrol concentrations ranging from 0.25 to 2.5 mM, for further optimizing the production of resveratrol-4'-O- β -D-glucuronide and resveratrol-3-O- β -D-glucuronide. The reactions were conducted at pH 6.5, OD₆₀₀ 10, and 40 °C for 3 hours. The conversion rates of resveratrol to its glucuronides were similar when the substrate concentration were 0.25 mM and 0.5 mM, namely 82.6 % to 83.2%. However, the conversion rate fell to 41.7% when the concentration of resveratrol was further increased to 1.0 mM (Fig. 8f). As a result, 0.5 mM was deemed to be the optimal substrate concentration according to the productivity of resveratrol glucuronides under the selected reaction conditions.

Finally, we scaled up the reaction to 1 L considering all the effects mentioned above. The titers of resveratrol-4'-O- β -D-glucuronide and resveratrol-3-O- β -D-glucuronide

were 0.194 ± 0.001 mM (equivalent to 78.381 ± 0.366 mg/L) and 0.037 ± 0.001 mM (equivalent to 14.991 ± 0.248 mg/L) from a total of 0.5 mM (equivalent to 114.125 mg/L) of resveratrol in 3 hours at 40 °C in 200 mM phosphate buffer (pH 6.5) with shaking at 250 rpm.

Discussion

Polyphenols, such as resveratrol, quercetin and curcumin from certain foods and dietary supplements, have promising biological activities. (Sauer and Plauth 2017). However, their health benefits in the human body are often limited due to poor water solubility. Glycosylation is an effective approach to improve the water solubility and bioavailability (Ren et al. 2022). Actinomycetes are well-known for their ability to biosynthesize novel and pharmaceutically relevant secondary metabolites with various bioactivities (Fidan et al. 2019). Among them, *Streptomyces* is widely used to produce industrially important bioactive molecules, such as streptomycin, avermectin and oxytetracycline. *S. chromofuscus* ATCC 49982 is a typical example which produces the anti-cholesterol polyketide natural product herboxidiene (Yu et al. 2013). In this study, five actinomycete strains were screened for the ability to biotransform resveratrol, and only *S. chromofuscus* ATCC 49982 was found to generate two glycosides, which were structurally characterized as resveratrol-3-O- β -D-glucuronide and resveratrol-4'-O- β -D-glucuronide, respectively. Resveratrol is a plant-derived stilbenoid with a variety of bioactivities, including antimicrobial, antiviral, anti-inflammatory, antioxidant, antiaging, anticancer, antiplatelet, phytoestrogenic, neuro-protective, and cardio-protective activities (Thuan et al. 2018; Yu et al. 2002). Its ubiquitous presence in diets

such as grapes, wine, olive oil, white tea, peanuts and cranberries has attracted considerable research interest (Pervaiz 2003; Wang et al. 2002). Nevertheless, its low bioavailability results in limited absorption after oral administration and impedes the formulation of functional foods. Furthermore, its sensitivity to air and light also hinders the nutraceutical and medicinal applications and exploitation of resveratrol (Francioso et al. 2014; Jeon et al. 2016; Uesugi et al. 2017).

Resveratrolside (resveratrol-4'-O- β -glucoside) and polydatin (resveratrol-3-O- β -glucoside) are two common water-soluble derivatives of resveratrol, and they exhibit anticancer and antioxidant activities. Moreover, they can prevent coronary heart diseases (Shimoda et al. 2013). In the meantime, resveratrolside and polydatin are more resistant to enzymatic oxidation than resveratrol (King et al. 2006). In other words, glycosylation of resveratrol can extend its half-life in the cell and maintains the beneficial antioxidant capacity and biological properties (Regev-Shoshani et al. 2003). As one of the most abundant forms of resveratrol in nature, polydatin is the major bioactive compound of *Polygonum cuspidatum* root which is used to treat cardiac ailments, including atherosclerosis and inflammation in Japanese and Chinese folk medicine (Romero-Pérez et al. 1999). While the two resveratrol glucuronides obtained in this work are structurally slightly different than the glucosides, it will be interesting to find out how these molecules perform *in vivo*. In fact, resveratrol-3-O- β -D-glucuronide and resveratrol-4'-O- β -D-glucuronide were previously reported to be the metabolites of resveratrol in the human body. While resveratrol has cytotoxicity to human peripheral blood mononuclear cells at 30 μ M, these glucuronides did not show

any cytotoxicity at 300 μ M. The ubiquitous human β -glucuronidase can convert the metabolites back to resveratrol locally or systematically *in vivo* (Wang et al. 2004). Therefore, the two resveratrol glucuronides may represent useful pro-drugs of resveratrol for clinical applications.

S. chromofuscus ATCC 49982 was also found to be able to glucuronidate other phenolic compounds, indicating that the dedicated UGT in this strain is flexible and can transfer the glucuronic acid moiety to different positions of phenolic compounds. Interestingly, vanillic acid-4-O- β -D-glucuronide and vanillic acid-7-O- β -D-glucuronide were synthesized when vanillic acid is used as the substrate. The production of vanillic acid-7-O- β -D-glucuronide is somewhat surprising as the sugar moiety was introduced to the carboxyl group, which is quite chemically different than the phenolic hydroxyl group, further indicating that the UGT in *S. chromofuscus* ATCC 49982 is a highly versatile enzyme. Encouraged by the high flexibility of this enzyme, we sought to find and identify the dedicated the UGT in *S. chromofuscus* ATCC 49982. We were able to spot the most possible glycosyltransferase gene responsible for the observed glucuronidation in this strain because that it is flanked by two UDP-glucuronic acid biosynthetic genes (*gcaD* and *gcaB*). This gene was cloned and expressed in *E. coli* BL21(DE3). The purified GcaC was functionally characterized as a versatile UGT, providing a reference enzyme for future investigation of more microbial UGTs.

UGTs play important roles in plant growth and development. They can also be a useful tool for structural modification of bioactive molecules in metabolic engineering

applications, because it can greatly change the bioactivity, solubility, or stability of metabolites (De Bruyn et al. 2015; Kren and Martínková 2001). For example, the sweetness and solubility were greatly improved from glycyrrhetic acid to its final product glycyrrhizin through two steps of glucuronidation, which is used as an anti-hepatitis agent and a sweetener worldwide (Xu et al. 2016). In fact, the two glucuronic acid moieties of glycyrrhizin also reduce the side-effects (Yonekura and Hanada 2011). Researchers found that glucuronidated anthocyanins showed improved color stability in response to light compared to its glucosylated form, indicating that UGTs may be used to stabilize natural colorants for industrial use, such as commercial food colorant products (Osmani et al. 2009). Glucuronidation can also improve the bioactivity of natural products. For instance, glucuronidated flavonoids exhibited relatively stronger inhibitory activity of amyloid β (A β) and human islet amyloid polypeptide (hIAPP) aggregation than their aglycons (Hmidene et al. 2017). More importantly, the conjugation location of glucuronidation can alter the biological effects. Morphine-6-glucuronide is a much more potent agonist than morphine itself, while morphine-3-glucuronide is an extremely potent antagonist (Paul et al. 1989; Smith et al. 1990). This finding indicates that glucuronides may have very distinctive effects themselves.

To explore the potential of GcaC as a useful biocatalytic tool, we investigated the substrate specificity of this enzyme. Although *in vitro* reaction results revealed that GcaC is a specific UDP-glucuronyltransferase, it showed high flexibility toward the sugar acceptor substrates. A variety of substrates, such as quercetin, ferulic acid, vanillic acid, curcumin, vanillin, chrysin, zearalenone and apigenin, can be accepted by GcaC

as sugar acceptors to yield various glucuronides. Compared to BpUGAT from plant red daisy (*Bellis perennis*) that is specific for anthocyanin glucuronidation (Sawada et al. 2005), GcaC showed relaxed substrate specificity to sugar acceptors. Interestingly, it was found that different products may be produced from the same substrates in the *in vivo* biotransformation by *S. chromofuscus* ATCC 49982 and *in vitro* reactions with purified GcaC, likely due to the availability of UDP-glucuronic acid and other factors in the cells. For example, quercetin-7-O- β -D-glucuronide and quercetin-3-O- β -D-glucuronide were obtained as the major products when quercetin was incubated with *S. chromofuscus* ATCC 49982. However, a total of six glucuronides were detected *in vitro* when quercetin was reacted with UDP-glucuronic acid in the presence of purified GcaC. Interestingly, among the six products, four monoglucuronides and two diglucuronides of quercetin were obtained based on LC-MS analysis. Similarly, *in vitro* reaction of GcaC with curcumin also yielded a monoglucuronide and a diglucuronide. These results indicated that GcaC is a highly versatile enzyme for the synthesis of glucuronides. Compared to the tedious chemical methods to synthesize glucuronides (Sharipova et al. 2017), discovery of GcaC provides an effective tool to prepare various glucuronides from different phenolic compounds in an environmental-friendly and efficient way.

The optimal *in vitro* enzymatic reactions and *in vivo* bioconversion conditions of GcaC were investigated in this work. The optimum reaction temperature and pH for this enzyme were found to be 7.5 and 30 °C in phosphate buffer, which are both slightly lower than BpUGAT from *B. perennis* (8.0 and 35 °C). However, these two UGTs have

different response to metal ions. For example, Ca^{2+} had an inhibitory effect on BpUGAT, but stimulated the activity of GcaC. Similarly, Mg^{2+} and Mn^{2+} , with negligible effects on the catalytic activity of BpUGAT (Sawada et al. 2005), enhanced the activity of GcaC. By contrast, the inhibitory effects of Cu^{2+} , Zn^{2+} and Fe^{2+} on GcaC is similar to the previous discovered UBGAT from *Scutellaria baicalensis* (Nagashima et al. 2000).

Generally, UGTs fulfill key metabolic functions in various organisms, and microbial UGTs are not well studied compared to those in mammalian systems. In the human body, the activity of UGTs can modify the lipid phase fluidity of the microsomal membrane, which is critical for its physiological function (Zakim and Vessey 1974). Mammalian UGTs play an important role in the elimination of xenobiotics and lipophilic compounds from the body, and the native acceptor substrates could be bilirubin, hormones, bile acids, retinoids, and thyroid hormones (Clarke et al. 1991; Radomska-Pandya et al. 1999). GcaC is a microbial UGT. Based on the BLAST analysis and enzymatic studies, we propose that the native function of GcaC is a UDP-glucuronyltransferase and might have the following potential functions: (1) GcaC contributes to the cell surface polysaccharide biosynthesis. Specifically, it may transfer sugars from intracellular nucleotide sugars to the lipid carrier acceptor in cytoplasmic membrane and then synthesize the long-chain polysaccharides such as exopolysaccharides, which are produced by many bacteria and excreted into the environment during growth (Li et al. 2010); (2) GcaC uses native peptidyl nucleosides as acceptor substrates, such as cytosine, to biosynthesize endogenous peptide-nucleoside antibiotics for defending themselves from other bacteria or fungi (Gould and

Guo 1994); (3) GcaC may catalyze the glucuronidation of lipophilic endogenous metabolites and xenobiotics, like some fungal UGTs, and may play a role in the degradation of carcinogenic pollutants in their surrounding environment. Additional work is required to identify the exact function of GcaC in *S. chromofuscus* ATCC 49982 (Bezalel et al. 1997; Wackett and Gibson 1982).

Even though some glucuronyltransferases have been found in the microorganisms, many of them require association with another enzyme to display the function (Tracy et al. 2007; Sugiura et al. 2010). Moreover, their functions are almost limited to the synthesis of saccharides (DeAngelis and White 2002; Wang et al. 2018; Wang et al. 2020). By contrast, GcaC represents a novel UGT from microorganism with broad substrate specificity and can glucuronylate various plant polyphenols. BLAST analysis showed that this microbial UGT showed little or no homology to UGTs from other sources. For example, GcaC has less than 25% identity to BpUGAT from *B. perennis* (Gene bank accession number AB190262) (Sawada et al. 2005), GuUGAT from *Glycyrrhiza uralensis* (Gene bank accession number KT759000) (Xu et al. 2016), and UBGAT from *Scutellaria baicalensis* (Gene bank accession number BAC98300) (Nagashima et al. 2000). Discovery and characterization of GcaC yielded a reference enzyme for future identification of additional UGTs from microorganisms. More importantly, this highly flexible enzyme may (1) glucuronidate a variety of substrates, (2) introduce the glucuronic acid moiety to different positions of a substrate, and (3) introduce one or two glucuronic acid moieties to a substrate to yield monoglucosides and diglucosides. Therefore, *S. chromofuscus* ATCC 49982, GcaC and *E. coli*

BL21(DE3)-GcaC can be used to prepare desired glucuronides from particular substrates. For example, vanillic acid-COOH-glucuronide was only previously detected in human urine after tea intake, and it was only identified by using MS analysis without available NMR data (Ridder et al. 2012; van der Hooft et al. 2012). This work for the first time biosynthesized vanillic acid-7-O- β -D-glucuronide for complete structure elucidation. This work also demonstrated that this novel UGT can be efficiently expressed in *E. coli* BL21(DE3) and the engineered strain can be used as a whole-cell biocatalyst to prepare resveratrol glucuronoides. The titers of resveratrol-4'-O- β -D-glucuronide and resveratrol-3-O- β -D-glucuronide were 78.381 ± 0.366 mg/L and 14.991 ± 0.248 mg/L from 114.125 mg/L resveratrol in a 1-L reaction system within 3 hours. Overall, this work provides a highly versatile UGT that can serve as a useful biocatalyst to prepare valuable glucuronides of bioactive molecules.

Author contributions JR and JZ conceived and designed research. JR, CB, and KS conducted experiments. JR and JZ analyzed data. JR, CB, KS and JZ wrote the manuscript. All authors read and approved the manuscript.

Funding information This work was supported by the National Science Foundation Award CBET-2044558. The Bruker Avance III HD Ascend-500 NMR instrument used in this research was funded by the National Science Foundation Award CHE-1429195.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval This article does not contain any studies with human participants

or animals performed by any of the authors.

Data availability statement All data generated or analyzed during this study are included in this published article (and its supplementary information files).

References

Almeida AF, Santos CuN, Ventura MR (2017) Synthesis of new sulfated and glucuronated metabolites of dietary phenolic compounds identified in human biological samples. *J Agric Food Chem* 65(31):6460–6466. <https://doi.org/10.1021/acs.jafc.6b05629>

Bezalel L, Hadar Y, Cerniglia CE (1997) Enzymatic mechanisms involved in phenanthrene degradation by the white rot fungus *Pleurotus ostreatus*. *Appl Environ Microbiol* 63(7):2495–2501. <https://doi.org/10.1128/aem.63.7.2495-2501.1997>

Bowles D, Isayenkova J, Lim E-K, Poppenberger B (2005) Glycosyltransferases: managers of small molecules. *Curr Opin Plant Biol* 8(3):254–263. <https://doi.org/10.1016/j.pbi.2005.03.007>

Briggs B, Baker P, Belvo M, Black T, Getman B, Kemp C, Muth W, Perun T, Strobel Jr R, Paschal J (1999) Microbial process for preparation of glucuronides of raloxifene. *J Ind Microbiol Biot* 23(3):194–197. <https://doi.org/10.1038/sj.jim.2900716>

Cai Z, Huang J, Luo H, Lei X, Yang Z, Mai Y, Liu Z (2013) Role of glucose transporters in the intestinal absorption of gastrodin, a highly water-soluble drug with good oral bioavailability. *J Drug Target* 21(6):574–580.

815 <https://doi.org/10.3109/1061186X.2013.778263>

816 Cassinelli G, Ballabio M, Grein A, Merli S, Rivola G, Arcamone F, Barbieri B, Bordoni
817 T (1987) A new class of biosynthetic anthracyclines: anthracyclinone
818 glucuronides. J Antibiot 40(7):1071–1074.
819 <https://doi.org/10.7164/antibiotics.40.1071>

820 Chung SY, Seki H, Fujisawa Y, Shimoda Y, Hiraga S, Nomura Y, Saito K, Ishimoto M,
821 Muranaka T (2020) A cellulose synthase-derived enzyme catalyses 3-O-
822 glucuronosylation in saponin biosynthesis. Nat Commun 11(1):1–11.
823 <https://doi.org/10.1038/s41467-020-19399-0>

824 Clarke DJ, George SG, Burchell B (1991) Glucuronidation in fish. Aquat Toxicol 20(1-
825 2):35–56. [https://doi.org/10.1016/0166-445X\(91\)90040-G](https://doi.org/10.1016/0166-445X(91)90040-G)

826 De Bruyn F, Maertens J, Beauprez J, Soetaert W, De Mey M (2015) Biotechnological
827 advances in UDP-sugar based glycosylation of small molecules. Biotechnol
828 Adv 33(2):288–302. <https://doi.org/10.1016/j.biotechadv.2015.02.005>

829 De Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Glucuronidation in
830 humans. Clin Pharmacokinet 36(6):439–452.
831 <https://doi.org/10.2165/00003088-199936060-00005>

832 DeAngelis PL, White CL (2002) Identification and molecular cloning of a heparosan
833 synthase from *Pasteurella multocida* type D. J Biol Chem 277(9):7209–7213.
834 <https://doi.org/10.1074/jbc.M112130200>

835 Engstrom KM, Daanen JF, Wagaw S, Stewart AO (2006) Gram scale synthesis of the
836 glucuronide metabolite of ABT–724. J Org Chem 71(22):8378–8383.

837 <https://doi.org/10.1021/jo0611972>

838 Fidan O, Yan R, Zhu D, Zhan J (2019) Improved production of antifungal angucycline
839 Sch47554 by manipulating three regulatory genes in *Streptomyces* sp. SCC-
840 2136. Appl Biochem Biotechnol 66(4):517–526.
841 <https://doi.org/10.1002/bab.1748>

842 Francioso A, Mastromarino P, Restignoli R, Boffi A, d’Erme M, Mosca L (2014)
843 Improved stability of trans-resveratrol in aqueous solutions by
844 carboxymethylated (1,3/1,6)- β -D-glucan. J Agric Food Chem 62(7):1520–1525.
845 <https://doi.org/10.1021/jf404155e>

846 Gachon CM, Langlois-Meurinne M, Saindrenan P (2005) Plant secondary metabolism
847 glycosyltransferases: the emerging functional analysis. Trends Plant Sci
848 10(11):542–549. <https://doi.org/10.1016/j.tplants.2005.09.007>

849 Gould S, Guo J (1994) Cytosylglucuronic acid synthase (cytosine: UDP-
850 glucuronosyltransferase) from *Streptomyces griseochromogenes*, the first
851 prokaryotic UDP-glucuronosyltransferase. J Bacteriol 176(5):1282–1286.
852 <https://doi.org/10.1128/jb.176.5.1282-1286.1994>

853 Harborne JB, Baxter H (1999) The handbook of natural flavonoids. Volume 1 and
854 Volume 2. John Wiley and Sons.

855 Hmidene AB, Hanaki M, Murakami K, Irie K, Isoda H, Shigemori H (2017) Inhibitory
856 activities of antioxidant flavonoids from *Tamarix gallica* on amyloid
857 aggregation related to Alzheimer's and type 2 diabetes diseases. Biol Pharm Bull
858 40(2):238–241. <https://doi.org/10.1248/bpb.b16-00801>

859 Imai H, Kitagawa M, Ishihara K, Masuoka N, Shimoda K, Nakajima N, Hamada H
860 (2012) Glycosylation of *trans*-resveratrol by plant-cultured cells. *Biosci*
861 *Biotech Bioch* 76(8):1552–1554. <https://doi.org/10.1271/bbb.120126>

862 Jeon YO, Lee J-S, Lee HG (2016) Improving solubility, stability, and cellular uptake of
863 resveratrol by nanoencapsulation with chitosan and γ -poly (glutamic acid).
864 *Colloids Surf B* 147:224–233. <https://doi.org/10.1016/j.colsurfb.2016.07.062>

865 Kaminaga Y, Nagatsu A, Akiyama T, Sugimoto N, Yamazaki T, Maitani T, Mizukami
866 H (2003) Production of unnatural glucosides of curcumin with drastically
867 enhanced water solubility by cell suspension cultures of *Catharanthus roseus*.
868 *FEBS Lett* 555(2):311–316. [https://doi.org/10.1016/S0014-5793\(03\)01265-1](https://doi.org/10.1016/S0014-5793(03)01265-1)

869 Kim S-K (2016) *Marine Enzymes Biotechnology: Production and Industrial*
870 *Applications, Part II-Marine Organisms Producing Enzymes, Volume 79, 1st*
871 *edition. Academic Press.*

872 King RE, Bomser JA, Min DB (2006) Bioactivity of resveratrol. *Compr Rev Food Sci*
873 *F* 5(3):65–70. <https://doi.org/10.1111/j.1541-4337.2006.00001.x>

874 Kren V, Martínková L (2001) Glycosides in medicine: “The role of glycosidic residue
875 in biological activity”. *Curr Med Chem* 8(11):1303–1328.
876 <https://doi.org/10.2174/0929867013372193>

877 Li X, Wang L, Bai L, Yao C, Zhang Y, Zhang R, Li Y (2010) Cloning and
878 characterization of a glucosyltransferase and a rhamnosyltransferase from
879 *Streptomyces* sp. 139. *J Appl Microbiol* 108(5):1544–1551.
880 <https://doi.org/10.1111/j.1365-2672.2009.04550.x>

881 Li Y, Baldauf S, Lim E-K, Bowles DJ (2001) Phylogenetic analysis of the UDP-
 882 glycosyltransferase multigene family of *Arabidopsis thaliana*. J Biol Chem
 883 276(6):4338–4343. <https://doi.org/10.1074/jbc.M007447200>
 884 Marvalin C, Azerad R (2011a) Microbial glucuronidation of polyphenols. J Mol Catal
 885 B Enzym 73(1-4):43–52. <https://doi.org/10.1016/j.molcatb.2011.07.015>
 886 Marvalin C, Azerad R (2011b) Microbial production of phase I and phase II metabolites
 887 of propranolol. Xenobiotica 41(3):175–186.
 888 <https://doi.org/10.3109/00498254.2010.535219>
 889 Mehnaz D, Abdulla K, Aiysha D, Zaheer A, Mukhtar S (2017) Actinomycetes: a source
 890 of industrially important enzymes. J Proteom Bioinform 10:12
 891 <https://doi.org/10.4172/JPB.1000456>
 892 Nagashima S, Hirotani M, Yoshikawa T (2000) Purification and characterization of
 893 UDP-glucuronate: baicalein 7-O-glucuronosyltransferase from *Scutellaria*
 894 *baicalensis* Georgi. cell suspension cultures. Phytochemistry 53(5):533–538.
 895 [https://doi.org/10.1016/S0031-9422\(99\)00593-2](https://doi.org/10.1016/S0031-9422(99)00593-2)
 896 Nawani N, Aigle B, Mandal A, Bodas M, Ghorbel S, Prakash D (2013) Actinomycetes:
 897 Role in biotechnology and medicine. BioMed Res Int 2013: 687190.
 898 <https://doi.org/10.1155/2013/687190>
 899 Osmani SA, Halkjær Hansen E, Malien-Aubert C, Olsen C-E, Bak S, Lindberg Møller
 900 B (2009) Effect of glucuronosylation on anthocyanin color stability. J Agric
 901 Food Chem 57(8):3149–3155. <https://doi.org/10.1021/jf8034435>
 902 Pandey RP, Parajuli P, Shin JY, Lee J, Lee S, Hong Y-S, Park YI, Kim JS, Sohng JK

903 (2014) Enzymatic biosynthesis of novel resveratrol glucoside and glycoside
 904 derivatives. *Appl Environ Microbiol* 80(23):7235–7243.
 905 <https://doi.org/10.1128/AEM.02076-14>
 906 Paul D, Standifer KM, Inturrisi CE, Pasternak G (1989) Pharmacological
 907 characterization of morphine-6 β -glucuronide, a very potent morphine
 908 metabolite. *J Pharmacol Exp Ther* 251(2):477-483.
 909 Pervaiz S (2003) Resveratrol: from grapevines to mammalian biology. *FASEB J*
 910 17(14):1975–1985. <https://doi.org/10.1096/fj.03-0168rev>
 911 Prakash D, Nawani N, Prakash M, Bodas M, Mandal A, Khetmalas M, Kapadnis B
 912 (2013) Actinomycetes: a repertory of green catalysts with a potential revenue
 913 resource. *Biomed Res Int* 2013:264020. <https://doi.org/10.1155/2013/264020>
 914 Priyadharsini P, Dhanasekaran D (2015) Diversity of soil allelopathic Actinobacteria in
 915 Tiruchirappalli district, Tamilnadu, India. *J Saudi Soc Agric Sci* 14(1):54–60.
 916 <https://doi.org/10.1016/j.jssas.2013.07.001>
 917 Radomska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI (1999)
 918 Structural and functional studies of UDP-glucuronosyltransferases. *Drug Metab*
 919 *Rev* 31(4):817–899. <https://doi.org/10.1081/DMR-100101944>
 920 Regev-Shoshani G, Shoseyov O, Bilkis I, Kerem Z (2003) Glycosylation of resveratrol
 921 protects it from enzymic oxidation. *Biochem J* 374(1):157–163.
 922 <https://doi.org/10.1042/bj20030141>
 923 Remya M, Vijayakumar R (2008) Isolation and characterization of marine antagonistic
 924 actinomycetes from west coast of India. *Med Biol* 15(1):13–19.

925 Ren J, Tang W, Barton CD, Price OM, Mortensen MW, Phillips A, Wald B, Hulme SE,
926 Stanley LP, Hevel J (2022) A highly versatile fungal glucosyltransferase for
927 specific production of quercetin-7-O- β -d-glucoside and quercetin-3-O- β -d-
928 glucoside in different hosts. Appl Microbiol Biotech 106(1):227–245.
929 <https://doi.org/10.1007/s00253-021-11716-x>

930 Rice-Evans C (2001) Flavonoid antioxidants. Curr Med Chem 8(7):797–807.
931 <https://doi.org/10.2174/0929867013373011>

932 Ridder L, van der Hooft JJ, Verhoeven S, de Vos RC, van Schaik R, Vervoort J (2012)
933 Substructure-based annotation of high-resolution multistage MSn spectral trees.
934 Rapid Commun Mass Sp 26(20):2461–2471. <https://doi.org/10.1002/rcm.6364>

935 Romero-Pérez AI, Ibern-Gómez M, Lamuela-Raventós RM, de la Torre-Boronat MC
936 (1999) Piceid, the major resveratrol derivative in grape juices. J Agric Food
937 Chem 47(4):1533–1536. <https://doi.org/10.1021/jf981024g>

938 Sauer S, Plauth A (2017) Health-beneficial nutraceuticals-myth or reality? Appl
939 Microbiol Biotechnol 101(3):951–961. [https://doi.org/10.1007/s00253-016-](https://doi.org/10.1007/s00253-016-8068-5)
940 8068-5

941 Sawada Sy, Suzuki H, Ichimaida F, Yamaguchi M-a, Iwashita T, Fukui Y, Hemmi H,
942 Nishino T, Nakayama T (2005) UDP-glucuronic acid: anthocyanin
943 glucuronosyltransferase from red daisy (*Bellis perennis*) flowers: enzymology
944 and phylogenetics of a novel glucuronosyltransferase involved in flower
945 pigment biosynthesis. J Biol Chem 280(2):899–906.
946 <https://doi.org/10.1074/jbc.M410537200>

947 Sharipova R, Andreeva O, Strobykina IY, Voloshina A, Strobykina A, Kataev V (2017)
 948 Synthesis and antimicrobial activity of glucuronosyl derivatives of
 949 steviolbioside from *Stevia rebaudiana*. Chem Nat Compd 53(6):1107–1111.
 950 <https://doi.org/10.1007/s10600-017-2211-0>
 951 Shimoda K, Hamada M, Hamada H, Takemoto M, Hamada H (2013) Synthesis of
 952 resveratrol glycosides by cultured plant cells. Nat Prod Commun 8(7):907–909.
 953 <https://doi.org/10.1177/1934578X1300800713>
 954 Smith MT, Watt JA, Cramond T (1990) Morphine-3-glucuronide-a potent antagonist of
 955 morphine analgesia. Life Sci 47(6):579–585. [https://doi.org/10.1016/0024-](https://doi.org/10.1016/0024-3205(90)90619-3)
 956 [3205\(90\)90619-3](https://doi.org/10.1016/0024-3205(90)90619-3)
 957 Stachulski A, Jenkins G (1998) The synthesis of O-glucuronides. Nat Prod Rep
 958 15(2):173–186.
 959 Stachulski AV, Harding JR, Lindon JC, Maggs JL, Park BK, Wilson ID (2006) Acyl
 960 glucuronides: biological activity, chemical reactivity, and chemical synthesis. J
 961 Med Chem 49(24):6931–6945. <https://doi.org/10.1021/jm060599z>
 962 Sugiura N, Baba Y, Kawaguchi Y, Iwatani T, Suzuki K, Kusakabe T, Yamagishi K,
 963 Kimata K, Kakuta Y, Watanabe H (2010) Glucuronyltransferase activity of KfiC
 964 from *Escherichia coli* strain K5 requires association of KfiA: KfiC and KfiA
 965 are essential enzymes for production of K5 polysaccharide, N-acetylheparosan.
 966 J Biol Chem 285(3):1597–1606. <https://doi.org/10.1074/jbc.M109.023002>
 967 Thilakarathna SH, Rupasinghe H (2013) Flavonoid bioavailability and attempts for
 968 bioavailability enhancement. Nutrients 5(9):3367–3387.

969 <https://doi.org/10.3390/nu5093367>

970 Thorson JS, Barton WA, Hoffmeister D, Albermann C, Nikolov DB (2004) Structure-

971 based enzyme engineering and its impact on *in vitro* glycorandomization.

972 ChemBioChem 5(1):16–25. <https://doi.org/10.1002/cbic.200300620>

973 Thuan NH, Trung NT, Cuong NX, Van Cuong D, Van Quyen D, Malla S (2018)

974 Escherichia coli modular coculture system for resveratrol glucosides production.

975 World J Microb Biot 34(6):1–13. <https://doi.org/10.1007/s11274-018-2458-z>

976 Tracy BS, Avci FY, Linhardt RJ, DeAngelis PL (2007) Acceptor specificity of the

977 *Pasteurella hyaluronan* and chondroitin synthases and production of chimeric

978 glycosaminoglycans. J Biol Chem 282(1):337–344.

979 <https://doi.org/10.1074/jbc.M607569200>

980 Tsao R (2010) Chemistry and biochemistry of dietary polyphenols. Nutrients

981 2(12):1231–1246. <https://doi.org/10.3390/nu2121231>

982 Uesugi D, Hamada H, Shimoda K, Kubota N, Ozaki S-i, Nagatani N (2017) Synthesis,

983 oxygen radical absorbance capacity, and tyrosinase inhibitory activity of

984 glycosides of resveratrol, pterostilbene, and pinostilbene. Biosci Biotechnol

985 Biochem 81(2):226–230. <https://doi.org/10.1080/09168451.2016.1240606>

986 Van der Hooft JJ, de Vos RC, Mihaleva V, Bino RJ, Ridder L, de Roo N, Jacobs DM,

987 van Duynhoven JP, Vervoort J (2012) Structural elucidation and quantification

988 of phenolic conjugates present in human urine after tea intake. Anal Chem

989 84(16):7263–7271. <https://doi.org/10.1021/ac3017339>

990 Wackett L, Gibson D (1982) Metabolism of xenobiotic compounds by enzymes in cell

991 extracts of the fungus *Cunninghamella elegans*. *Biochem J* 205(1):117–122.
 992 <https://doi.org/10.1042/bj2050117>
 993 Wang L-X, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield R (2004) Resveratrol
 994 glucuronides as the metabolites of resveratrol in humans: characterization,
 995 synthesis, and anti-HIV activity. *J Pharm Sci* 93(10):2448–2457.
 996 <https://doi.org/10.1002/jps.20156>
 997 Wang T-T, Deng J-Q, Chen L-Z, Sun L, Wang F-S, Ling P-X, Sheng J-Z (2020) The
 998 second member of the bacterial UDP-N-acetyl-D-glucosamine: heparosan
 999 alpha-1, 4-N-acetyl-D-glucosaminyltransferase superfamily: GaKfiA from
 1000 *Gallibacterium anatis*. *Int J Biol Macromol* 147:170–176.
 1001 <https://doi.org/10.1016/j.ijbiomac.2020.01.016>
 1002 Wang T-T, Zhu C-Y, Zheng S, Meng C-C, Wang T-T, Meng D-H, Li Y-J, Zhu H-M,
 1003 Wang F-S, Sheng J-Z (2018) Identification and characterization of a chondroitin
 1004 synthase from *Avibacterium paragallinarum*. *Appl Microbiol Biotech*
 1005 102(11):4785–4797. <https://doi.org/10.1007/s00253-018-8926-4>
 1006 Wang Y, Catana F, Yang Y, Roderick R, Van Breemen R (2002) Analysis of resveratrol
 1007 in grape products, cranberry juice and wine using liquid chromatography-mass
 1008 spectrometry. *J Agric Food Chem* 50:431–435.
 1009 <https://doi.org/10.1021/jf010812u>
 1010 Weymouth-Wilson AC (1997) The role of carbohydrates in biologically active natural
 1011 products. *Nat Prod Rep* 14(2):99–110. <https://doi.org/10.1039/NP9971400099>
 1012 Wilkinson SM, Liew CW, Mackay JP, Salleh HM, Withers SG, McLeod MD (2008)

1013 *Escherichia coli* glucuronylsynthase: an engineered enzyme for the synthesis of
1014 β -glucuronides. Org Lett 10(8):1585–1588. <https://doi.org/10.1021/ol8002767>
1015 Wilkinson SM, Watson MA, Willis AC, McLeod MD (2011) Experimental and kinetic
1016 studies of the *Escherichia coli* glucuronylsynthase: An engineered enzyme for
1017 the synthesis of glucuronide conjugates. J Org Chem 76(7):1992–2000.
1018 <https://doi.org/10.1021/jo101914s>
1019 Xu G, Cai W, Gao W, Liu C (2016) A novel glucuronosyltransferase has an
1020 unprecedented ability to catalyse continuous two-step glucuronosylation of
1021 glycyrrhetic acid to yield glycyrrhizin. New Phytol 212(1):123–135.
1022 <https://doi.org/10.1111/nph.14039>
1023 Yonekura K, Hanada K (2011) An evolutionary view of functional diversity in family
1024 1 glycosyltransferases. Plant J 66(1):182–193. [https://doi.org/10.1111/j.1365-](https://doi.org/10.1111/j.1365-313X.2011.04493.x)
1025 [313X.2011.04493.x](https://doi.org/10.1111/j.1365-313X.2011.04493.x)
1026 Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, Hirschelman WH, Pezzuto JM,
1027 Mehta RG, van Breemen RB (2002) Human, rat, and mouse metabolism of
1028 resveratrol. Pharm Res 19(12):1907–1914.
1029 <https://doi.org/10.1023/A:1021414129280>
1030 Yu D, Xu F, Zhang S, Shao L, Wang S, Zhan J (2013b) Characterization of a
1031 methyltransferase involved in herboxidiene biosynthesis. Bioorg Med Chem
1032 Lett 23(20):5667–5670. <https://doi.org/10.1016/j.bmcl.2013.08.023>
1033 Zakim D, Vessey DA (1974) Membrane dependence of uridine diphosphate
1034 glucuronyltransferase: Effect of the membrane on kinetic properties. Biochem

1035 Soc Trans 2(6):1165–1167. <https://doi.org/10.1042/bst0021165>

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

Table 1 The glucuronidation (*gca*) gene cluster in *S. chromofuscus* ATCC 49982.

| Gene | Size (aa) | Predicted function | Homolog/source/NCBI accession no. | Identity/ Similarity |
|-------------|--------------|---------------------------------------|--|-------------------------|
| <i>gcaA</i> | 230 | TetR family transcriptional regulator | TetR family transcriptional regulator/ <i>Streptomyces</i> sp. CRXT-G- 22]/WP_187751940.1 | 71%/81% |
| <i>gcaB</i> | 484 | UDP-Glucose dehydrogenase | UDP-glucose/GDP-mannose dehydrogenase family protein/ <i>Streptomyces</i> sp. SolWspMP-5a-2 /WP_093832645.1 | 82%/86% |
| <i>gcaC</i> | 402 | UDP-Glucuronyltransferase | UDP-glucuronyl/UDP- glucosyltransferase/ <i>Streptomyces</i> <i>malaysiensis</i> /NIY63294.1 | 70%/80% |
| <i>gcaD</i> | 320 | UDP-Glucose pyrophosphorylase | GalU/ <i>Streptococcus</i> <i>pneumonia</i> /AJ004869.1 | 45%/62% |
| <i>gcaE</i> | 540 | MFS transporter | MFS transporter/ <i>Streptomyces</i> <i>hygroscopicus</i> /WP_060945424.1 | 83%/90% |

Figure legends

Fig. 1 Screening of five actinomycete strains for the ability to biotransform resveratrol.

a HPLC analysis (300 nm) of biotransformation of resveratrol by five actinomycete strains. (i) resveratrol + YM medium; (ii) resveratrol + *S. roseum* No. 79089; (iii) resveratrol + *S. resei* ATCC 53903; (iv) resveratrol + *A. hibisca* P157-2; (v) resveratrol + *Streptomyces* sp. FERM BP-2474; (vi) resveratrol + *S. chromofuscus* ATCC 49982. **b** UV spectra comparison of the substrate and product **1**. **c** UV spectra comparison of the substrate and product **2**. **d** ESI-MS (-) spectrum of product **1**. **e** ESI-MS (-) spectrum of product **2**.

Fig. 2 Key HMBC correlations of **1-7**.

Fig. 3 HPLC analysis of glucuronidation of different substrates by *S. chromofuscus* ATCC 49982. **a** Glucuronidation of quercetin (350 nm); **b** Glucuronidation of ferulic acid (300 nm); **c** Glucuronidation of vanillic acid (300 nm). (i) substrate + YM medium; (ii) substrate + *S. chromofuscus* ATCC 49982.

Fig. 4 A putative glucuronidation (*gca*) gene cluster discovered in *S. chromofuscus* ATCC 49982. **a** Organization of the *gca* gene cluster. **b** Proposed pathways for UDP-glucuronic acid biosynthesis and glucuronidation of resveratrol.

Fig. 5 Heterologous expression and *in vitro* functional characterization of GcaC. **a** SDS-PAGE analysis of the purified recombinant GcaC from *E. coli* BL21(DE3). Lane 1: Purified GcaC; Lane 2: Protein ladder. **b** HPLC analysis (300 nm) of the *in vitro* reaction of GcaC with resveratrol. (i) resveratrol + reaction buffer without GcaC; (ii) resveratrol + GcaC. **c** ESI-MS (-) spectrum of *in vitro* product **1**. **d** ESI-MS (-) spectrum

of *in vitro* product 2.

Fig. 6 HPLC analysis of *in vitro* glucuronidation of different sugar acceptor substrates by GcaC. **a** Glucuronidation of quercetin (350 nm); **b** Glucuronidation of ferulic acid (300 nm); **c** Glucuronidation of vanillic acid (300 nm). **d** Glucuronidation of curcumin (420 nm); **e** Glucuronidation of vanillin (300 nm); **f** Glucuronidation of chrysin (350 nm); **g** Glucuronidation of zearalenone (250 nm); **h** Glucuronidation of apigenin (350 nm). (i) substrate incubated with the reaction buffer without GcaC; (ii) substrate incubated with the reaction buffer with GcaC.


Fig. 7 Determination of the optimum *in vitro* reaction conditions for GcaC. **a** Effect of reaction temperature on the GcaC glucuronidation activity. **b** Effect of reaction pH on the GcaC glucuronidation activity. **c** Effect of metal ions on the GcaC glucuronidation activity. Data are presented as the mean \pm SD from three independent experiments.

Fig. 8 Optimization of *in vivo* production of resveratrol glucuronides by *E. coli* BL21(DE3)/pJR36. **a** HPLC analysis (300 nm) of resveratrol glucuronidation by GcaC in *E. coli* BL21(DE3). (i) Commercial standard of resveratrol; (ii) resveratrol + *E. coli* BL21(DE3)/pET28a; (iii) resveratrol + *E. coli* BL21(DE3)/pJR36. **b** Effect of cell density on resveratrol glucuronidation **c** Effect of reaction pH on resveratrol glucuronidation by *E. coli* BL21(DE3)/pJR36. **d** Effect of temperature on resveratrol glucuronidation by *E. coli* BL21(DE3)/pJR36. **e** Effect of reaction time on resveratrol glucuronidation by *E. coli* BL21(DE3)/pJR36. **f** Effect of substrate concentration on resveratrol glucuronidation by *E. coli* BL21(DE3)/pJR36. Data are presented as the mean \pm SD from three independent experiments.

1115

1116

1117



1118

1119 **Fig. 1**

1120

1121





Fig. 2

1143

1144

1145



1146

1147 **Fig. 3**

1148

1149

1150

1151

a



b




Fig. 4





Fig. 5

1182

1183

1184



1185 **Fig. 6**

1186


1187

1188

1189

1190

1191



1192 **Fig. 7**


1193

1194

1195

1196

1197



1198 **Fig. 8**

1199

1200

1201